LWM
VRTX icon

Laidlaw Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Laidlaw Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-575
Closed -$232K – 163
2024
Q4 		$232K Sell
575
-128
-18% -$59.3K 0.1% 156
2024
Q3 		$327K Hold
703
– – 0.16% 125
2024
Q2 		$330K Hold
703
– – 0.18% 124
2024
Q1 		$294K Sell
703
-523
-43% -$221K 0.16% 142
2023
Q4 		$499K Buy
+1,226
New +$453K 0.18% 127
2023
Q3 		– Sell
-1,072
Closed -$377K – 373
2023
Q2 		$377K Buy
1,072
+37
+4% +$12.5K 0.07% 229
2023
Q1 		$326K Sell
1,035
-40
-4% -$12K 0.07% 249
2022
Q4 		$310K Buy
1,075
+127
+13% +$38.7K 0.07% 265
2022
Q3 		$274K Buy
948
+214
+29% +$61.6K 0.06% 255
2022
Q2 		$207K Sell
734
-140
-16% -$37.5K 0.04% 341
2022
Q1 		$228K Buy
+874
New +$207K 0.04% 349

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Laidlaw Wealth Management's VRTX Position: Q1 2025 in Review

Laidlaw Wealth Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2025, closing a stake of 575 shares — an estimated $232K sold.

Laidlaw Wealth Management first reported a position in VRTX in Q1 2022 and held it in 11 quarters. The position peaked at $499K in Q4 2023. 1,612 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

  • Laidlaw Wealth Management reported no remaining Vertex Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Laidlaw Wealth Management sold 575 Vertex Pharmaceuticals shares in Q1 2025, an estimated $232K.
  • Laidlaw Wealth Management first reported a position in Vertex Pharmaceuticals in Q1 2022 and held it in 11 quarters.
  • Laidlaw Wealth Management's Vertex Pharmaceuticals position peaked at $499K in Q4 2023.
  • 1,612 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Laidlaw Wealth Management's 13F filing for Q1 2025, filed 16 May 2025.